For the control groups, 120 patients with EGFR-mutant lung adenocarcinoma [40 men and 80 women; mean age of 62 years (range of 28–83 years)] were randomly chosen based on the prevalence of genetic mutations in the lung cancer population study16. The gene discussed is EGFR; the disease is lung adenocarcinoma.